Neurodegenerative Diseases News and Research

RSS

New therapeutic approaches to protect neurons from inflammation and toxicity-induced neurodegeneration

New research led by Chu Chen, PhD, Associate Professor of Neuroscience at LSU Health Sciences Center New Orleans, provides evidence that one of the only naturally occurring fatty acids in the brain that has the ability to interact with the receptors originally identified as the targets of THC (the psychoactive component of marijuana) can help to protect brain cells from neurodegenerative diseases like Alzheimer's and Parkinson's.

20 Aug 2008

Huntington's disease brain damage linked to overactive immune response in the bloodstream

The damage to brain tissue seen in Huntington's disease may be caused by an overactive immune response in the bloodstream and the brain, according to new findings from two teams of researchers at the University of Washington in Seattle and University College London. The findings will be published online July 14 in the Journal of Experimental Medicine.

14 Jul 2008

Neuron to publish Prana's PBT2 preclinical research on Alzheimer's disease

Prana Biotechnology Ltd. has announced the publication of key research findings with its lead Alzheimer's Disease drug, PBT2.

10 Jul 2008

Neuroscientists pinpoint how neural activity boosts blood flow to the brain

New research from Harvard University neuroscientists has pinpointed exactly how neural activity boosts blood flow to the brain. The finding has important implications for our understanding of common brain imaging techniques such as fMRI, which uses blood flow in the brain as a proxy for neural activity.

26 Jun 2008

Nerve cells derived from stem cells may one day provide improved brain treatments

Scientists at the Burnham Institute for Medical Research have, for the first time, genetically programmed embryonic stem (ES) cells to become nerve cells when transplanted into the brain, according to a study published in The Journal of Neuroscience.

24 Jun 2008

Nerve cells derived from embryonic stem cells and transplanted into mice may lead to improved brain therapies

24 Jun 2008

New clues for nerve cell repair

A new study at the Montreal Neurological Institute at McGill University identifies a key mechanism for the normal development of motor nerve cells (motor neurons) - cells that control muscles. This finding is crucial to understanding and treating a range of conditions involving nerve cell loss or damage, from spinal cord injury to neurodegenerative diseases such as ALS, also known as Lou Gehrig's disease.

3 Jun 2008

Intracellular antibody mops up mutant protein in Huntington's disease model

Scientists have created a tool for mopping up the clumps of mutant protein that drive neurodegeneration in Huntington's disease. Emory University researchers engineered a virus to make an intracellular antibody or "intrabody" against huntingtin, the protein whose mutant forms poison the brain cells of people with Huntington's.

26 May 2008

The emerging role of infection in Alzheimer’s

A number of chronic diseases are in fact caused by one or more infectious agents. For example, stomach ulcers are caused by Helicobacter pylori, chronic lung disease in newborns and chronic asthma in adults are both caused by Mycoplasmas and Chlamydia pneumonia, while some other pathogens have been associated with atherosclerosis. The realization that pathogens can produce slowly progressive chronic diseases has opened new lines of research into Alzheimer's disease.

25 May 2008

Yerkes researchers develop first transgenic nonhuman primate model of Huntington's disease

In the first study of its kind, researchers at the Yerkes National Primate Research Center, Emory University, in collaboration with researchers from the Department of Human Genetics at Emory's School of Medicine, have developed the first transgenic nonhuman primate model of Huntington's disease (HD), one of the most devastating human neurodegenerative diseases.

22 May 2008

Drug testing for exam students could be on the cards

Experts are warning that schools and universities may soon need to test students sitting exams for drugs, in much the same way that athletes are currently tested.

22 May 2008

Plant flavonoid luteolin reduces inflammatory response in the brain

Researchers at the University of Illinois report this week that a plant compound found in abundance in celery and green peppers can disrupt a key component of the inflammatory response in the brain. The findings have implications for research on aging and diseases such as Alzheimer's and multiple sclerosis.

20 May 2008

Discovery of mechanism of action of antibiotic able to reduce neuronal cell death in brain

Virginia Commonwealth University researchers have discovered how an antibiotic works to modulate the activity of a neurotransmitter that regulates brain functions, which eventually could lead to therapies to treat Alzheimer's disease, Huntington's disease, epilepsy, stroke, dementia and malignant gliomas.

11 May 2008

microRNAs appear essential for retinal health

Retinas in newborn mice appear perfectly fine without any help from tiny bits of genetic material called microRNAs except for one thing - the retinas do not work.

7 May 2008

Enkephalin pathway shows potential as new target for Alzheimer's

Alzheimer's disease (AD) is an incurable disease that is increasing in prevalence and will increase even more rapidly as the Baby Boom generation enters the age of highest risk. The available AD drugs are only partially effective in some patients. New strategies are urgently needed.

7 May 2008

Prana Biotechnology has discovered novel drug candidates for use in Parkinson's disease

Prana Biotechnology Limited has announced that it has identified novel therapeutic drug candidates from its Parkinson's disease program. Already, a lead candidate drug has demonstrated positive effects in pre-clinical studies, protecting the brain from damage to the substantia nigra, the area of the brain affected in Parkinson's disease.

6 May 2008

Raptor Pharmaceuticals initiates phase IIa clinical study for Convivia

Raptor Pharmaceuticals Corp. has announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. , has initiated the Company's first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole ("4-MP") in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia program.

21 Apr 2008

Yeast cells used to screen for potential Lou Gehrig's disease drugs

Researchers from the University of Pennsylvania School of Medicine are developing a novel approach to screen for drugs to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, using yeast cells.

17 Apr 2008

Inserting tiny scaffolding into the brain could dramatically reduce damage caused by strokes

With funding from the Biotechnology and Biological Sciences Research Council (BBSRC) neurobiologists from the Institute of Psychiatry and tissue engineers from The University of Nottingham have joined forces to tackle the challenge of tissue loss as a result of stroke.

13 Apr 2008

Tiny scaffolding inserted into brain could reduce damage caused by strokes

Inserting tiny scaffolding into the brain could dramatically reduce damage caused by strokes the UK National Stem Cell Network Annual Science Meeting will hear today (10 April).

10 Apr 2008